Abstract: In 2020, the number of registered and approved drug varieties and innovative drugs in Jiangsu province ranked the first in China, and the quality and efficacy consistency evaluation of generic drugs was also leading in the country. In order to ensure the normal process of drug registration and approval during the prevention and control of COVID-19, Jiangsu Medical Products Administration actively cooperated with the Center for Food and Drug Inspection of the National Medical Products Administration for drug registration verification of more than one-fourth of the total amount of work in the country, with drug re-registration work being completed on time and the annual number of drug varieties produced in Jiangsu province accounting for 42.6%. We will continue to promote the reform of "streamlining administration, delegating power, strengthening regulation, and improving services", further deepen the reform of the review and approval system, and continuously optimize the business environment in the province.